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Altered and Conventional Fractionated Radiotherapy in Locoregional 
Control and Survival of Patients with Squamous Cell Carcinoma of 
the Larynx, Oropharynx, and Hypopharynx
Aim To compare the efficacy of two altered fractionation radiotherapy treat-
ment protocols (hyperfractionation and accelerated fractionation with con-
comitant boost) with conventional fractionation in improvement of locore-
gional disease control and survival of patients with squamous cell carcinoma 
of the larynx, oropharynx, or hypopharynx.
Methods From March 1999 to December 2000, 51 patients with previously 
untreated squamous cell carcinoma of the larynx, oropharynx or hypopharynx 
underwent conventionally fractionated radiotherapy and received 66-70 Gy 
in 6½-7 weeks (2 Gy per fraction a day, 5 fractions a week). From January 
2001 to June 2004, 101 patients with the same diagnoses underwent either 
hyperfractionated radiotherapy, with 74.4-79.2 Gy delivered in 6.2-7 weeks 
(1.2 Gy per fraction twice a day), or accelerated fractionation with concomi-
tant boost, which delivered 68.7-72 Gy in 6 weeks (1.8 Gy per fraction a day 
and 1.5 Gy per fraction a day to a boost filed as a second daily treatment for 
the last 11-12 treatment days). Locoregional relapse and overall survival were 
recorded.
Results Complete response to treatment was obtained in 31 of 51 patients 
treated with conventional fractionation, 33 of 50 patients treated with hy-
perfractionation, and 36 of 51 patients treated with accelerated fractionation. 
No significant differences were observed among the patients treated with con-
ventional, hyperfractionated, or accelerated radiotherapy modalities either in 
locoregional control rate (41% vs 35% vs 49%, respectively; P = 0.690) or 
overall survival rate (50% vs 40% vs 51%, respectively; P = 0.760). The grade 
of acute reactions of the larynx significantly differed among the treatment 
groups (Fisher exact test; P = 0.039). The difference in the grade of acute side 
effects in the skin among the treatment groups was of borderline significance 
(χ22 test; P = 0.054). There was also a borderline difference among the groups 
in the grade of late side effects in the mucous membrane (χ22 test; P = 0.055).
Conclusion Altered fractionation regimens were not more efficacious than 
conventional fractionation in the treatment of previously untreated head and 
neck carcinoma.
Clinical Trial Registration ClinicalTrials.gov Identifier:  NCT00291434
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Irrespectively of the modality of primary 
treatment for head and neck squamous cell carci-
noma, local or locoregional residual or recurrent 
tumors represent the major cause of treatment 
failure, emphasizing the role of locoregional con-
trol for the patients’ long-term survival (1). Pri-
mary definitive radiotherapy used as a single 
treatment modality in patients with head and 
neck cancer is expected to allow preservation of 
the form and function of organs in this region 
(2). Primary definitive radiotherapy in the treat-
ment of early stages of squamous cell carcino-
ma of the larynx, oropharynx or hypopharynx 
achieves equal probability of tumor control as 
surgery does. Large primary tumors and/or ad-
vanced neck disease treated with primary defin-
itive radiotherapy demand delivery of large total 
doses of irradiation to enhance the tumor con-
trol. Considering the results of conventionally 
fractionated radiotherapy, rational modification 
of radiation fractionation regimens has been in-
tensively investigated for more than three de-
cades, with an aim to improve the outcome of 
patients with locally advanced head and neck car-
cinomas (3).
The two prototypes of altered radiation frac-
tionation regimens are hyperfractionation and 
accelerated fractionation. Hyperfractionation 
increases locoregional control of the diseases by 
increasing total tumor dose delivered, where-
as accelerated fractionation should increase the 
control by counteracting the accelerated tumor 
clonogen proliferation during irradiation and 
uses a shortened overall treatment time (4-6). 
Large randomized trials showed that a number 
of altered fractionation schedules improved the 
locoregional control rates, but had only a modest 
impact on survival (7,8).
The aim of our study was to evaluate two dif-
ferent altered fractionation regimens – hyper-
fractionation and accelerated fractionation with 
concomitant boost as a late accelerating compo-
nent – in comparison with conventional frac-
tionation in primary definitive radiotherapy of 
patients with squamous cell carcinomas of the 
larynx, oropharynx or hypopharynx.
Patients and methods
Patients
The study conducted at the Institute of Ra-
diotherapy and Oncology in Skopje from March 
1999 to June 2004 involved 152 consecutive, 
previously untreated patients with histological-
ly proved squamous cell carcinoma of the lar-
ynx, oropharynx or hypopharynx. There were 
137 men and 15 women aged between 36 and 
74 years (median age, 58.3 years). The inclusion 
criteria were age 18-75 years, Karnofsky perfor-
mance score ≥60% (9), and all stages of the dis-
ease except stage IVC. Disease staging was done 
according to TNM classification of Internation-
al Union Against Cancer (UICC) and Ameri-
can Joint Committee of Cancer (AJCC) from 
1997 (10). Patients with previous or concurrent 
malignancy other then basal cell carcinoma were 
excluded.
Pretreatment diagnostic work-up other than 
medical history and physical examination includ-
ed panendoscopy with tumor biopsies for histo-
logical proof, neck ultrasound and fine-needle 
biopsy for cytological proof of cervical metasta-
ses, blood chemistries, chest x-ray, and liver ultra-
sound. The extent of the disease was also defined 
by computed tomography scanning and/or mag-
netic resonance imaging.
Treatment assignment
Eligible patients admitted from March 1999 
to December 2000 were treated with conven-
tionally fractionated radiotherapy. Eligible pa-
tients admitted between January 2001 and June 
2004 were first stratified by site of cancer origin 
(larynx vs oropharynx vs hypopharynx), Karnof-
sky performance score (60-70% vs 80-100%), 
and stage of disease (I and II vs III and IV) and 
then randomly assigned to either hyperfraction-
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ation regimen or accelerated fractionation with 
concomitant boost regimen and followed up. Ex-
ceptions occurred when patients either refused 
treatment with two daily fractions or were not 
offered twice-a-day irradiation because of lack of 
machine time.
Radiotherapy regimens
Cobalt-60 machine was used for irradiation 
therapy. The conventionally fractionated radio-
therapy schedule was 66-70 Gy in 6½-7 weeks 
(one fraction of 2 Gy a day, 5 fractions per week), 
whereas the hyperfractionation treatment sched-
ule was 74.4-79.2 Gy in 6.2-7 weeks (two frac-
tions of 1.2 Gy a day, 10 fractions per week, with 
an interfraction interval of at least 6 hours; Fig-
ure 1). The treatment schedule in accelerated 
fractionation with concomitant boost consisted 
of a fraction of 1.8 Gy a day, 5 days a week, up 
to 32.4 Gy, including all sites of disease and elec-
tively irradiated areas of the neck, followed by 
two daily fractions for the last 11-12 days. The 
first daily fraction delivering dose of 1.8 Gy en-
compassed all sites of the disease and electively 
irradiated neck nodes. The second daily fraction 
was the concomitant boost delivered through 
reduced fields to encompass the gross disease 
only, delivering a fraction of 1.5 Gy up to a total 
of 68.7-72 Gy in 6 weeks (Figure 1). The inter-
val between the two daily fractions was at least 6 
hours.
The use of therapeutic ionizing radiation 
leads to cell killing. In radiotherapy the most im-
portant biologic endpoint is loss of cellular re-
productive ability or clonogenicity. When a pop-
ulation of cells is irradiated, a proportion of cells 
sustain injury lethal to their reproductive integ-
rity, while the remaining proportion retains the 
ability to reproduce indefinitely, which is the 
endpoint for survival most commonly used in ra-
diobiology (11). The linear-quadratic model al-
lows for analysis of the relationship between cell 
survival and radiation dose. In this widely accept-
ed model in radiobiology, the cell survival is ap-
proximated mathematically by the following for-
mula: SFd = exp (-αd -βd
2), where SFd is surviving 
fraction of target cells after a dose per fraction 
d is given (12,13). The equation for cell survival 
describes logarithmic cell killing by two coeffi-
cients, α for single hit killing (a linear function of 
dose) and β for multihit killing (a function of the 
square of the dose) (13). In fractionated irradia-
tion, each successive fraction in a series is equally 
effective, ie, the same proportion of cells is killed 
for a given dose increment (11,14). According 
to the linear-quadratic model, the survival curve 
continuously bends and its shape is determined 
by the α/β ratio. The dimensions of α/β ratio are 
Gy. This is the dose at which the linear contri-
bution to damage (αd on the logarithmic scale) 
equals the quadratic contribution (βd2) (12).
The therapeutic use of ionizing radiations 
is predicated on sparing normal tissue while at-
tempting to achieve lethal effects on tumor cells 
(15). When fractionated irradiation is used, re-
sponses to fractionation are different in differ-
ent types of tissues. The three generic tissue types 
are (a) early-responding normal tissues, charac-
terized by rapid cell turnover, such as skin, mu-
cosa, intestinal epithelia, and hemopoetic system; 
Figure 1. Schematic illustration of the fractionation regimens used. Each bar repre-
sents one radiation fraction. Bars above the lines represent large field irradiation and 
those bellow the lines stand for coned-down boost irradiation.
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(b) late-responding normal tissues, characterized 
by slow rate of renewal, such as spinal cord, kid-
ney, and dermis; and (c) tumors, as a general class 
(13,16). In the linear-quadratic model, the values 
for α/β ratio for early-responding tissues are high, 
10 Gy, and for late-responding tissues are lower, 
2-4 Gy. This implies that the cell killing that un-
derlies acute radiation responses is a result of ir-
reparable single-hit mechanisms. In terms of cell 
survival curve shapes, the target cells in early-re-
sponding tissues have a relatively long initial lin-
ear region, whereas the curve for slowly respond-
ing tissues is “curvier.” Thus, the fractionation 
effect is relatively smaller in early-responding tis-
sues than in late-responding tissues (13). This is 
reflected in isoeffect curves, which show the rela-
tionships between total doses and dose per frac-
tion for early- and late-responding tissues. The 
isoeffective total doses increase more rapidly 
with decrease in dose per fraction for late effects 
than for early effects. In terms of fractionation 
response, tumors tend to behave like early-re-
sponding tissues, providing that late reactions are 
dose-limiting (4).
Hyperfractionation is based on the differ-
ence between the fractionation response of ear-
ly- and late-responding tissues. A therapeutic 
benefit of hyperfractionation can be achieved if 
tumors have small fractionation sensitivity char-
acterized by α/β values greater than the α/β val-
ues that characterize the fractionation sensitivity 
of late-responding normal tissues (17). Hyper-
fractionation is generally expected to allow for an 
escalation of total dose, thereby increasing tumor 
control rate without increasing the risk of late 
complications (5).
The biologic equivalence sought in the con-
ventional and hyperfractionated regimens is in 
their late effects. The value for α/β ratio for late-
responding tissues used in our calculations was 
3.5 Gy (α/β for head and neck various late ef-
fects) (14).
The calculation of biologically effective dose 
(BED) (18) as a measure of the effect of a course 
of irradiation was done by using the following 
formula: BED = D [1 + d/ (α/β)], where D is 
the total dose in n fractions of size d.
The calculated BED for late effects in the 
conventionally fractionated regimen was 112 
Gy. The calculated BED for the late effects in the 
hyperfractionation regimen was 103 Gy. The cal-
culated BED for the tumor using α/β ratio of 10 
Gy was 84 Gy for the conventional fractionation 
and 88.7 Gy for the hyperfractionation. Accord-
ing to these calculations, the conventional frac-
tionation seemed to be less effective for tumor 
effects than hyperfractionation protocol and, in 
addition, it appeared around 8% more damaging 
for late-responding tissues.
The accelerated fractionation, which uses a 
reduced overall treatment time below the con-
ventional 7 weeks, should increase tumor cure 
rates by restricting the time available for tumor 
cell proliferation. Using the accelerated fraction-
ation with concomitant boost as a late accelerat-
ing component we shortened the overall treat-
ment time by one week. Considering the effect 
of proliferation being equivalent to the loss of 
radiation dose of about 0.6 Gy per day (6), the 
dose in this 6-week schedule would be effective-
ly larger than that in a 7-week schedule by factor 
0.6 × (7-6) × 7 = 4.2 Gy, or 6% of a convention-
al treatment of 70 Gy. The use of the concomi-
tant boost in the last 12 days of the course of ra-
diotherapy seems to be a biologically reasonable 
strategy. In normal tissues with earliest response, 
a repopulation response probably begins with-
in about 2 weeks from the start of radiotherapy 
(6). Withers et al (19) concluded that there was 
no repopulation by clonogenic mucosal epitheli-
al cells during the first 12-14 days of a 2.0 Gy per 
fraction regimen, 5 times per week, but thereaf-
ter, mucosal isoeffect dose increases by about 7.0 
Gy/week between the third and seventh week of 
irradiation. Since the accelerated repopulation 
as a regenerative response of the mucous mem-
branes is already in full swing by the time of the 
concomitant boost, the tolerance should be im-
Croat Med J 2006;47:42-52
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proved. Hence, delivering the boost during the 
last part of the basic treatment course has the 
greatest probability of insuring that the full dose 
will be given without treatment interruption 
(13,20).
Radiotherapy was delivered by cobalt-60 ma-
chine with a source-to-surface or source-to-iso-
center distance of 80 cm. Lateral opposing fields 
were used to treat the primary tumor and the 
lymph nodes in the upper neck. Elective low-
neck radiation therapy was realized through a 
single anterior field. There was no elective nod-
al irradiation in patients with early glottic can-
cer (T1 and T2 primary tumors). All fields were 
treated on each treatment day. A shrinking-field 
technique was adopted for all patients. The first 
field reduction off the spinal cord occurred at 46 
Gy for conventional fractionation, 45.6 for hy-
perfractionation, and 45 Gy for accelerated frac-
tionation. The second field reduction occurred 
at 56 Gy for conventional fractionation and 55-
57.6 Gy for hyperfractionation. Electrons or par-
tial semi field technique were used for boosting 
the dose to involved nodes in spinal chains, while 
protecting the cord. These fields and the low 
neck field were treated once a day.
Follow-up and treatment response
According to our follow-up policy, all pa-
tients were followed by both ear, nose and throat 
(ENT) surgeons and radiation oncologists. Dur-
ing the radiological treatment, patients were ex-
amined weekly. The patients were seen for clin-
ical examination monthly during the first year 
after they completed the treatment, every other 
month in the second year, every 4 months in the 
third year, every 6 months in the fourth and fifth 
year, and annually thereafter.
Tumor response was documented by direct 
measurement at every examination. When fea-
sible, biopsy was performed of clinically suspect-
ed persistence or regrowth of the tumor, but sys-
tematic biopsies were not performed. Patients 
were considered to have achieved an initial com-
plete primary response if the primary disease to-
tally disappeared after radiotherapy. A complete 
nodal response was similarly defined for patients 
with initial involvement of neck lymph nodes. 
A patient was considered a “complete respond-
er” when both complete primary and nodal re-
sponse was achieved. For estimating the locore-
gional control rates, the following definitions for 
failures were used: patients who initially achieved 
only partial response to the planned radiothera-
py were considered failures on study day 1; pa-
tients who did achieve an initial complete re-
sponse were considered as failures on the study 
day when a recurrence either at the primary site 
of tumor or the lymph node was first reported. 
Locoregional control was defined as persisting 
tumor clearance above clavicles after complete 
response at the end of radiation therapy.
Assessment of treatment toxicity
Acute reactions of skin, mucous membrane, 
salivary glands, pharynx and larynx were eval-
uated according to the scales of the European 
Organization for Research and Treatment of 
Cancer/Radiation Therapy Oncology Group 
(EORTC/RTOG) (15) and scored weekly dur-
ing the course of radiotherapy and monthly dur-
ing the first 2 months after irradiation. Late ra-
diation changes in the skin, subcutaneous tissue, 
and mucous membrane were also graded accord-
ing to the same criteria (15), beginning 6 months 
after the end of radiotherapy.
Statistical analysis
Data were presented as mean ± standard de-
viation (SD). Association between categorical 
data was analyzed with contingency tables and 
χ2 test (21). Fisher exact test was used when con-
tingency tables had expected frequencies of <5 
(21-24). Differences of means between the three 
treatment groups were tested with ANOVA 
(25). Actuarial locoregional control and survival 
curves were plotted according to Kaplan-Meier 
method (26) and compared by the log-rank test 
47
Krstevska and Crvenkova: Altered Fractionation Radiotherapy in Throat Cancer
(25). The rates of locoregional control and over-
all survival are reported as 95% confidence inter-
vals (95% CI). The statistical analyses were done 
by the BioMeDical (BMDP) statistical software 
package (27) and specially designed software for 
Kaplan-Meier estimation and graphic presenta-
tion (28), including the log-rank test for com-
parison of locoregional control and survival (29). 
Post hoc power calculation was performed for all 
comparisons with G*Power (http://www.psycho.
uni-duesseldorf.de/aap/projects/gpower/), PS Pow-
er (http://biostat.mc.vanderbilt.edu/twiki/bin/vie 
w/Main/PowerSampleSize), and NCSS/PASS 
Power Analysis Statistical Software 2005 (NCSS, 
Kaysville, UT, USA).
Results
The three treatment groups did not signifi-
cantly differ in sex, age, and performance status 
(P = 0.802, P = 0.630, and P = 0.851, respec-
tively; Table 1). The distribution of tumor-re-
lated variables such as site, T stage, N stage, and 
UICC/AJCC stage were not significantly dif-
ferent in the three treatment groups (P>0.95, 
P>0.95, P = 0.932, and P = 0.921, respectively; 
Table 2).
All patients in each treatment group complet-
ed the assigned treatment in accordance with the 
protocol or with minor variations. The mean to-
tal dose delivered at mid-depth of the central axis 
of the parallel-opposed fields was 69.4 ± 1.34 Gy 
for patients irradiated with conventional frac-
tionation, 78.4 ± 1.40 Gy for patients receiv-
ing hyperfractionation, and 70.4 ± 9.08 Gy 
for patients treated with accelerated fraction-
ation. The average overall treatment time was 
52.5 ± 4.10 days for patients treated with con-
ventionally fractionated radiotherapy, hyperfrac-
tionation was accomplished in an average time of 
48.0 ± 3.81 days, and accelerated fractionated ra-
diotherapy was completed in 43.3 ± 3.41 days. 
There was a significant difference between the 
overall treatment time and fractionation regimen 
accomplished (ANOVA; P<0.001).
Outcome
Complete primary response was achieved in 
31 of 51 patients treated with conventional frac-
tionation, 33 of 50 patients assigned to hyper-
fractionation, and 36 of 51 patients assigned to 
accelerated fractionation. The complete nodal re-
sponse rates were obtained in 16 of 27 patients 
treated with conventional fractionation, 19 of 29 
patients treated with hyperfractionation, and 18 
of 25 patients treated with accelerated fraction-
Table 1. Pretreatment characteristics of the patients undergoing 
radiotherapy for cancer of the larynx, oropharynx or hypop-
harynx according to fractionation regimen










 male 45 45 47
 female  6  5  4
Age (y):
  ≤40  2  1  3
 41-70 45 43 40
 >70  4  6  8
Karnofsky performance 
status (%):*
 60-70  8 10  9
 80-100 43 40 42
*Karnofsky performance status according to ref. 9.
Table 2. Cancer characteristics according to fractionation 
regimen










 larynx 28 27 29
 oropharynx 16 17 16
 hypopharynx  7  6  6
T stage:
 T1  2  2  1
 T2  9 11 10
 T3 26 24 28
 T4 14 13 12
N stage:
 N0 24 21 26
 N1  7  8  6
 N2 15 13 12
 N3  5  8  7
UICC/AJCC* stage:
 I  2  2  1
 II  8 10  7
 III 18 15 21
 IV 23 23 22
*International Union Against Cancer (UICC) and American Joint Committee of 
Cancer (AJCC) classification of TNM stages.
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ation. Complete nodal response with persistent 
primary lesion was present in 4 of 16 patients 
treated conventionally, 2 of 19 patients treat-
ed with hyperfractionation, and 6 of 18 patients 
treated with accelerated fractionation. The “com-
plete responders” rate within 2 months from the 
end of radiotherapy was 31 of 51 in the group of 
patients treated with conventional fractionation, 
33 of 50 in the group irradiated with hyperfrac-
tionation, and 36 of 51 in the accelerated frac-
tionation group. The median follow-up was 23 
months (range, 6-64).
No significant differences in locoregional 
control and overall survival rates were found be-
tween the three treatment modalities (log-rank 
test; P = 0.690 and P = 0.760, respectively). The 
2-year locoregional control rate was 41.0% (95% 
CI, 27.5-54.5) for the patients treated with con-
ventionally fractionated radiotherapy. The 2-year 
locoregional control rate was 35.2% (95% CI, 
22.0-48.4) for the patients irradiated with hyper-
fractionation and 48.7% (95% CI, 35.0-62.4) for 
the patients irradiated with accelerated fraction-
ation (Figure 2). The overall survival rate at two 
years was 50.2% (95% CI, 36.5-63.9) for the pa-
tients irradiated with conventional fractionation, 
40.1% (95% CI, 26.6-53.6) for the patients treat-
ed with hyperfractionation, and 50.5% (95% CI, 
36.8-64.2) for the patients treated with acceler-
ated radiotherapy (Figure 3). Subgroup analy-
sis according to UICC/AJCC stage also did not 
show significant differences between the three 
treatment groups in locoregional control (log-
rank test; P = 0.310 for stages I and II; log-rank 
test; P = 0.330 for stages III and IV) and survival 
(log-rank test; P = 0.290 for stages I and II; log-
rank test; P = 0.150 for stages III and IV).
Patterns of failure
The recurrence at the primary site and the si-
multaneous manifestation of local and nodal re-
currence were the most common patterns of fail-
ure (Table 3). One patient in the group treated 
with hyperfractionation developed recurrent tu-
mor in the neck nodes only. Two patients in the 
conventionally treated group, one patient in the 
group treated with hyperfractionation, and two 
patients in the group irradiated with accelerated 
fractionation had developed distant metastases 
without locoregional failure (Table 3).
Figure 2. Locoregional control according to fractionation regimen (Ka-
plan-Meier estimates). Log-rank test; χ22 = 0.760; P = 0.690.
Figure 3. Overall survival according to fractionation regimen (Kaplan-
Meier estimates). Log-rank test; χ22 = 0.640; P = 0.760.
Table 3. Recurrence and metastases of cancer of the larynx, 
oropharynx or hypopharynx in patients with complete primary 
and nodal response according to fractionation regimen









Local recurrence 5 3 5
Regional recurrence 0 1 0
Distant metastases 2 1 2
Locoregional recurrence 4 4 5




 and distant metastases
1 1 0
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Side effects
Acute side effects. The worst grades of acute 
side effects (Grade 3) during the treatment and 
up to 2 months after irradiation were most com-
monly found in the mucous membrane and the 
pharynx (Table 4). We did not find any signifi-
cant difference in the distribution of acute reac-
tions of the mucous membrane, salivary glands, 
and pharynx among the three fractionation reg-
imens (Fisher exact test; P = 0.510 and χ22 test; 
P = 0.325, P = 0.560, respectively). There was a 
significant difference in the grade of acute reac-
tions in the larynx among the three treatment 
groups (Fisher exact test; P = 0.039), whereas 
the difference in the grade of acute reactions of 
the skin was of borderline significance (χ22 test; 
P = 0.054). In comparison with the convention-
al fractionation group, the altered fractionation 
groups had slightly worse Grade 2 acute side ef-
fects.
Late side effects. The worst late side effects 
(Grade 3) were most commonly found in the 
mucous membrane (Table 5). No significant 
difference existed among the three treatment 
groups in the late reactions in the skin and in the 
subcutaneous tissue (Fisher exact test; P = 0.520 
and P = 0.071, respectively). There was a border-
line significant difference in the grade of late ef-
fects in the mucous membrane among the three 
fractionation groups (χ22 test; P = 0.055). The 
Grade 3 mucosal reactions were slightly worse 
in altered fractionation groups as compared with 
conventional fractionation group.
Discussion
Our results did not show any significant dif-
ference between conventional fractionation and 
hyperfractionation or accelerated fractionation 
in locoregional control and overall survival rates 
of patients with squamous cell carcinoma of the 
larynx, oropharynx or hypopharynx. Similar find-
ings were obtained in the Toronto randomized 
trial (30). However, our results were opposite to 
those of four other randomized trials (31-34), 
which showed that hyperfractionation improved 
either locoregional control or survival rates in pa-
tients with head and neck squamous cell carci-
noma. The EORTC 22791 trial with the longest 
follow-up showed a 5-year local control rate of 
59% in patients treated with hyperfractionation, 
compared with 40% rate in patients treated with 
conventional treatment (32). An improvement 
in 5-year overall survival was also reported for 
Table 4. Acute reactions to radiotherapy according to fractiona-
tion regimen










 1 29 20 26
 2 16 19 23
 3  6 11  2
Mucous membrane:
 0  9  7  7
 1  3  4  3
 2 19 12 11
 3 20 27 30
Salivary gland:
 0 16 11 12
 1 23 18 24
 2 12 21 15
Pharynx:
 1  9  6  8
 2 26 20 23
 3 16 24 20
Larynx:
 0  3  3  1
 1 33 18 21
 2 11 22 24
 3  4  7  5
Table 5. Late reactions to radiotherapy according to fractionati-
on regimen










 0 16  9 10
 1 24 26 28
 2 10 11 12
 3  1  4  1
Subcutaneous tissue:
 0 26 21 17
 1 21 21 21
 2  3  4 12
 3  1  4  1
Mucous membrane:
 0 11 10  9
 1 12  5  4
 2 23 24 21
 3  5 11 17
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patients treated with hyperfractionation (32). 
In the Radiation Therapy Oncology Group trial 
(RTOG 9003) of 1073 patients, the locoregional 
control significantly increased with the increase 
in the total dose without changing the overall 
time using hyperfractionation, but no difference 
was found in the overall survival between hyper-
fractionation and conventional fractionation 
treatment groups (35). The role of hyperfrac-
tionation in the control of head and neck cancer 
has been controversial (36). Two different meta-
analyses came to different conclusions regarding 
the role of hyperfractionation (5,17), whereas 
EORTC 22791 and RTOG 9003 trials togeth-
er provided evidence of the efficacy of hyperfrac-
tionation compared to standard fractionation.
Results of randomized trials of accelerat-
ed fractionation are less consistent since there 
are numerous ways to accelerate treatment (37-
39). We adopted the concept of acceleration us-
ing concomitant boost and administering it dur-
ing the last 2˝ weeks of treatment, because it has 
been proved most efficacious (40). The results 
of our study did not show significant difference 
in the outcome of patients treated with acceler-
ated fractionation compared with conventional 
fractionation, which is in accordance with pre-
vious findings (41). In contrast, Ang et al (40) 
and Johnson et al (38) obtained significantly bet-
ter locoregional control and survival rates in pa-
tients irradiated with accelerated fractionation 
with concomitant boost than in those treated 
with conventional fractionation. The results of 
RTOG 9003 trial also confirmed that accelerat-
ed fractionation with concomitant boost could 
improve the therapeutic gains achievable with ir-
radiation. Locoregional control significantly in-
creased in patients treated with accelerated frac-
tionation with concomitant boost compared 
with standard fractionation, but there was no sig-
nificant difference in the overall survival (35).
In our study, the most common sites of 
Grade 3 acute reactions were the mucous mem-
brane and the pharynx, which is in accordance 
with other studies (34,35,37,41). The most com-
mon site of Grade 3 late side effects was the mu-
cous membrane. This is opposite to the results of 
RTOG 9003 trial (35) where the most common 
sites of Grade 3 late effects were the pharynx and 
the salivary gland. In our study, moderately en-
hanced Grade 2 acute reactions were observed in 
the skin and the larynx of patients in the altered 
fractionation groups compared with those in the 
conventional fractionation group. In contrast, 
Horiot et al (37) and Johnson et al (38) reported 
significant enhancement of acute reactions of the 
mucous membrane in the altered fractionation 
groups. In our study, Grade 3 late mucosal reac-
tions were modestly enhanced in the altered frac-
tionation groups compared to the conventional 
fractionation group. Significant difference in late 
mucosal reactions between altered fractionation 
group and conventional fractionation group has 
been reported by Fu et al (35) and Horiot et al 
(37). Antognoni et al (41) reported greater pro-
portion of mild complications of skin and sali-
vary glands in patients treated with accelerated 
fractionation, but found no differences in other 
normal tissues.
Chemotherapy applied concurrently with ir-
radiation improves survival compared with radi-
ation alone (42). The use of more toxic simulta-
neous radiochemotherapy protocols and altered 
fractionated irradiation increases the risk of se-
vere acute normal tissue reactions, which rep-
resent the major limitation of these treatment 
modalities (43). On the other hand, modern 
conformal and intensity-modulated radiother-
apy techniques diminish the incidence of severe 
acute side effects of irratiation in normal tissues. 
Conformal radiotherapy has the capability of 
improving tumor coverage while minimizing the 
dose to and volume of the surrounding normal 
tissues irradiated (44). Intensity-modulated ra-
diotherapy can achieve higher total doses in tu-
mors while sparing more normal tissue by deliv-
ering larger doses per fraction to the tumor only, 
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while maintaining lower doses per fraction to 
subclinical disease and normal tissues (45).
One of the possible limitations of our study 
was that treatment was delivered by Cobalt-60 
machine, but we expected that fractionated ir-
radiation delivered by new, more sophisticated 
machines would produce similar results. Anoth-
er limitation could be a relatively small sample 
size of our patient groups. However, the fact that 
we found no differences among the groups could 
not be attributed to the low power of the study. 
Although it was performed post hoc, power calcu-
lation in our study was sufficiently high, ranging 
between 70% and 90%. Furthermore, our find-
ings were in accordance with results of some of 
larger trials.
In conclusion, our findings did not indicate 
that the therapeutic effects of evaluated altered 
fractionation schedules were different from those 
of conventional treatment schedule. However, 
we support the implementation of conformal ra-
diotherapy for patients with previously untreat-
ed head and neck squamous cell carcinoma as it 
leaves open the possibility of improvement of 
their outcome.
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